The New Normal in Clinical Trials: Decentralized Studies
- PMID: 32869367
- DOI: 10.1002/ana.25892
The New Normal in Clinical Trials: Decentralized Studies
References
-
- Broderick Joseph P, Elm Jordan J, Janis LS, et al. National Institutes of Health StrokeNet during the time of COVID-19 and beyond. Stroke 2020;51:2580-2586.
-
- U.S. Food and Drug Administration. FDA guidance on conduct of clinical trials of medical products during COVID-19 public health emergency. 2020. https://www.fda.gov/regulatory-information/search-fda-guidance-documents.... . Accessed April 28, 2020.
-
- European Medicines Agency. Points to consider on implications of Coronavirus disease (COVID-19) on methodological aspects of ongoing clinical trials. 2020 https://www.ema.europa.eu/en/documents/scientific-guideline/points-consi.... Accessed April 28, 2020.
-
- Doherty GJ, Goksu M, de Paula BHR. Rethinking cancer clinical trials for COVID-19 and beyond. Nat Cancer 2020;1:568-572.
-
- Waterhouse DM, Harvey RD, Hurley P, et al. Early impact of COVID-19 on the conduct of oncology clinical trials and long-term opportunities for transformation: findings from an American Society of Clinical Oncology survey. JCO Oncol Pract 2020;16:417-421.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical